The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy

Maturitas

Volumn 43, Issue 3, 2002, Pages 183-194

  Reynolds, Robert F ^a   Obermeyer, Carla Makhlouf ^b,c   Walker, Alexander M ^b   Guilbert, Daniel ^d  

^a PFIZER INC   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Fallon Clinic   (United States)

Author keywords

Decision making; HMO; Hormone therapy; Menopause; Patient compliance

Indexed keywords

CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; HORMONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DECISION MAKING; DEMOGRAPHY; DISEASE SEVERITY; DRUG USE; FEMALE; HAZARD ASSESSMENT; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MENSTRUATION; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTION; PRESCRIPTION; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; SYMPTOM; TIME; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MASSACHUSETTS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUESTIONNAIRES; TREATMENT REFUSAL;

EID: 0037145932     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00204-9     Document Type: Article

References (56)

1. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Int. Med. 117:1992;1016-1037.
2. Col N.F., Pauker S.G., Goldberg R.J., Eckman M.H., Orr R.K., Ross E.M., et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch. Intern. Med. 159:1999;1458-1466.
3. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;453-461.
4. Clinical Synthesis Panel on HRT. Hormone replacement therapy. Lancet 1999; 354:152-55.
5. Grodstein F., Stampfer M.J., Falkeborn M., Naessen T., Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 5:1999;476-480.
6. Westendorp I.C.D., Veld B.A., Grobbe D.R., Pols H.A.P., Meijer W.T., Hofman A., et al. Hormone replacement therapy and peripheral arterial disease. Arch. Intern. Med. 160:2000;2498-2502.
7. Sourander L., Rajala T., Raiha I., Maiken J., Erkkola R., Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 352:1998;1965-1969.
8. Folsom A.R., Mink P.J., Sellers T.A., Hong C.P., Zheng W., Potter J.D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am. J. Public Health. 85:1995;1128-1132.
9. PEPI Investigators, Espeland M.A., Marcovina S.M., Miller V., Wood P.D., Wasilauskas C., Sherwin R., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 97:1998;979-986.
10. Andersen L.F., Gram J., Skouby S.O., Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am. J. Obstet. Gynecol. 180:1999;283-289.
11. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin on heart disease risk factors in postmenopausal women: postmenopausal estrogen/progestin intervention (PEPI) trial. JAMA. 273:1995;199-208.
12. HERS Writing Group, Hulley S., Grady D., Bush T., Furberg C., Herrington D., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;606-613.
13. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
14. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
15. Stanford J.L., Weiss N.S., Voigt L.F., Daling J.R., Habel L.A., Rossing M.A. Combined estrogen and progesting hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 274:1995;137-179.
16. Colditz G.A., Hankinson S.E., Hunter D.J., Willet W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1995;1589-1593.
17. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
18. Jick H., Derby L.E., Myers M.W., Wasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
19. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
20. Hunter M.S., O'Dea I., Britten N. Decision-making and hormone replacement therapy: a qualitative analysis. Soc. Sci. Med. 45:1997;1541-1548.
21. Kaufert P., Boggs P., Ettinger B., Woods N.F., Utian W. Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause. 4:1998;197-202.
22. Lock M. Encounters with aging: mythologies of menopause in Japan and North America. 1993;University of California Press, Berkeley.
23. Martin E. The woman in the body: a cultural analysis of reproduction. 1992;Beacon Press, Boston.
24. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.
25. Jeffe D.B., Freiman M., Fisher E.B. Women's reasons for using postmenopausal hormone replacement therapy: preventative medicine or therapeutic aid? Menopause. 3:1996;106-116.
26. Newton K.M., LaCroix A.Z., Leveille S.G., Rutter C., Keenan N.L., Anderson L.A. Women's beliefs and decisions about hormone replacement therapy. J. Womens Health. 6:1997;459-465.
27. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J. Womens Health. 4:1995;143-148.
28. Ettinger B., Li D., Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause. 3:1996;185-189.
29. Mansfield P.K., Voda A.M. Hormone use among middle-aged women: results of a three-year study. Menopause. 1:1994;99-108.
30. Berman R.S., Epstein R.S., Lydick E.G. Compliance of women in taking estrogen replacement therapy. J. Womens Health. 5:1996;213-220.
31. Faulkner D.L., Young C., Hutchins D., McCollam J.S. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause. 5:1998;226-229.
32. MacLennan A.H., MacLennan A., Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas. 16:1993;175-183.
33. Limouzin-Lamothe M. What women want from hormone replacement therapy: results of an international study. Eur. J. Obstet. Gynecol. Repro. Bio. S64:1996;S21-S24.
34. Ryan P.J., Harrison R., Blake G.M., Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br. J. Obstet. Gynaecol. 99:1992;325-328.
35. Gass M.L.S., Rebar R.W., Liu J.H., Cedars M.I. Characteristics of women who continue using hormone replacement therapy. Menopause. 4:1997;9-23.
36. Ravnikar V.A. Compliance with hormone therapy. Am. J. Obstet. Gynecol. 156:1997;1332-1334.
37. Wren B.G., Brown L. Compliance with hormonal replacement therapy. Maturitas. 13:1991;17-21.
38. Hahn R.G. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 161:1989;1854-1858.
39. Woods N.F., Saver B., Taylor T. Attitudes toward menopause and hormone therapy among women with access to health care. Menopause. 5:1998;178-188.
40. Johannes C.B., Crawford S.L., Posner J.G., McKinlay S.M. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am. J. Epi. 140:1994;439-452.
41. Brett K., Madans J. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epi. 145:1997;536-545.
42. Ettinger B., Pressman A., Bradley C. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen. Menopause. 5:1998;152-156.
43. Berman R.S., Epstein R.S., Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J. Womens Health. 6:1997;219-226.
44. Brett K., Madans J. Differences in use of postmenopausal hormone replacement therapy by black and white women. Menopause. 4:1997;66-70.
45. Reynolds R.F., Walker A.M., Obermeyer C.M., Rahman O., Guilbert D. Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. J. Clin. Epi. 54:2001;1056-1064.
46. Reynolds R.F., Obermeyer C.M., Walker A.M., Guilbert D. Side effects and sociobehavioral factors associated with postmenopausal hormone therapy discontinuation in Massachusetts. Menopause. 8:2001;189-199.
47. Walsh J.M.E., Brown J.S., Rubin S., Kagawa M., Grady D. Postmenopausal hormone therapy: factors influencing women's decision making. Menopause. 4:1997;39-45.
48. Zhang P., Tao G., Anderson L.A. Prevalence of and factors associated with hormone replacement therapy counseling: results from the 1994 National Health Interview Survey. Am. J. Public Health. 89:1999;1575-1577.
49. Ettinger B., Woods N.F., Barrett-Connor E., Pressman A. The North American Menopause Society 1998 Menopause Survey: Part II. Counseling about hormone replacement therapy: association with socioeconomic status and access to medical care. Menopause. 7:2000;143-148.
50. Newton K.M., Lacroix A.Z., Leveille S.G., Rutter C., Keenan N.L., Anderson L.A. The physician's role in women's decision making about hormone replacement therapy. Obstet. Gynecol. 92:1998;580-584.
51. Allison P.D. Discrete-time methods for the analysis of event histories. Leinhardt S., Sociologic methodology. 1982;61-98 Jossey-Bass, San Francisco.
52. Allison P.D. Event history analysis. 1984;Sage, Beverly Hills.
53. Hosmer D., Lemeshow S. Applied logistic regression. 1989;Wiley, New York.
54. StataCorp. Stata Statistical Software: Release 6.0. College Station, Texas: Stata Corporation, 1999.
55. Hunter M.S., O'Dea I. Perception of future health risks in mid-aged women: estimates with and without behavioural changes and hormone replacement therapy. Maturitas. 33:1999;37-43.
56. Brambilla D.J., McKinlay S. A comparison of responses to mailed questionnaires and telephone interviews in a mixed mode health survey. Am. J. Epi. 126:1987;962-971.